SCHEMBL4318085

SCHEMBL4318085

O=C1CCN(S(=O)(=O)c2ccc(CNC(=O)c3ccc(Cl)cc3)s2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK9 P45984 1/20 0.60
▸ MAPK10 P53779 1/20 0.60
▸ KMT2A Q03164 3/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ KDM4E B2RXH2 2/20 0.48
▸ ALDH1A1 P00352 3/20 0.47
▸ POLB P06746 1/20 0.47
▸ BCL2 P10415 1/20 0.46
▸ BCL2L1 Q07817 1/20 0.46
▸ LMNA P02545 2/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ APOBEC3A P31941 1/20 0.44
▸ APOBEC3G Q9HC16 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ ERAP1 Q9NZ08 1/20 0.44
▸ MAPT P10636 1/20 0.43
▸ HTT P42858 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ EPHX2 P34913 1/20 0.42
▸ USP5 P45974 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313979 0.94 MAPK9 (0.56) MAPK9MAPK10KMT2AMEN1KDM4E
SCHEMBL2428799 0.89 MAPK9 (0.61) MAPK9MAPK10KMT2AMEN1KDM4E
SCHEMBL2425870 0.87 MAPK9 (0.60) MAPK9MAPK10KMT2AMEN1KDM4E
SCHEMBL2423054 0.86 MAPK9 (0.59) MAPK9MAPK10KMT2AMEN1KDM4E
SCHEMBL2426655 0.86 MAPK9 (0.66) MAPK9MAPK10KMT2AMEN1KDM4E
SCHEMBL6431701 0.86 MAPK9 (0.59) MAPK9MAPK10KMT2AMEN1KDM4E
SCHEMBL7894669 0.86 MAPK9 (0.59) MAPK9MAPK10KMT2AMEN1ALDH1A1
SCHEMBL2426036 0.84 MAPK9 (0.64) MAPK9MAPK10KMT2AMEN1ALDH1A1
SCHEMBL2424858 0.83 MAPK9 (0.61) MAPK9MAPK10KMT2AMEN1KDM4E
SCHEMBL3480648 0.83 MAPK9 (0.60) MAPK9MAPK10KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1322642-B1 Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of Protein Jun-kinases MERCK SERONO SA (CH) 2013-09-04 — — EP disclosed
US-7544700-B2 Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein JunKinases LABORATOIRES SERONO SA (CH) 2009-06-09 — — US disclosed
US-20040077854-A1 Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moietties as inhibitors of protein junkinases MERCK SERONO SA (CH) 2004-04-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077854-A1 Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moietties as inhibitors of protein junkinases MAPK1, MAP3K1, MAPKAPK2 MAPK9 9/4885MAPK10 80/4885KMT2A 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback